Pharvaris N.V.
PHVS
$14.00
$0.282.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 60.54% | 59.70% | 43.92% | 35.29% | 20.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.26% | 46.11% | 51.40% | 35.98% | 21.52% |
| Operating Income | -64.26% | -46.11% | -51.40% | -35.98% | -21.52% |
| Income Before Tax | -3.72% | -78.65% | -34.51% | -24.39% | 13.31% |
| Income Tax Expenses | 64.09% | 58.92% | -25.85% | 376.15% | 159.85% |
| Earnings from Continuing Operations | -5.10% | -78.53% | -34.25% | -25.33% | 11.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.10% | -78.53% | -34.25% | -25.33% | 11.97% |
| EBIT | -64.26% | -46.11% | -51.40% | -35.98% | -21.52% |
| EBITDA | -64.23% | -46.41% | -51.73% | -36.30% | -21.51% |
| EPS Basic | 14.49% | -35.09% | 13.99% | 21.13% | 32.64% |
| Normalized Basic EPS | 15.62% | -35.15% | 13.84% | 21.73% | 33.66% |
| EPS Diluted | 14.49% | -35.09% | 13.99% | 21.13% | 32.64% |
| Normalized Diluted EPS | 15.62% | -35.15% | 13.84% | 21.73% | 33.66% |
| Average Basic Shares Outstanding | 22.91% | 32.17% | 56.09% | 58.91% | 30.70% |
| Average Diluted Shares Outstanding | 22.91% | 32.17% | 56.09% | 58.91% | 30.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |